



Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience

Francesco Pepe · Gianluca Russo · Alessandro Venuta · Claudia Scimone · Mariantonia Nacchio · Pasquale Pisapia · Gaia Goteri · Francesca Barbisan · Caterina Chiappetta · Angelina Pernazza · Domenico Campagna · Marco Giordano · Giuseppe Perrone · Giovanna Sabarese · Annalisa Altimari · Dario de Biase · Giovanni Tallini · Daniele Calistri · Elisa Chiadini · Laura Capelli · Alfredo Santinelli · Anna Elisa Gulini · Elisa Pierpaoli · Manuela Badiali · Stefania Murru · Riccardo Murgia · Elena Guerini Rocco · Konstantinos Venetis · Nicola Fusco · Denise Morotti · Andrea Gianatti · Daniela Furlan · Giulio Rossi · Laura Melocchi · Maria Russo · Caterina De Luca · Lucia Palumbo · Saverio Simonelli · Antonella Maffè · Paola Francia di Celle · Tiziana Venesio · Maria Scatolini · Enrico Grosso · Sara Orecchia · Matteo Fassan · Mariangela Balistreri · Elisabetta Zulato · Daniela Reghellin · Elena Lazzari · Maria Santacatterina · Maria Liliana Piredda · Manuela Riccardi · Licia Laurino · Elena Roz · Domenico Longo · Daniela Petronilla Romeo · Carmine Fazzari · Andrea Moreno-Manuel · Giuseppe Diego Puglia · Andrey D. Prjibelski · Daria Shafranskaya · Luisella Righi · Angela Listì · Domenico Vitale · Antonino Iaccarino · Umberto Malapelle · Giancarlo Troncone

Received: September 8, 2023 / Accepted: November 2, 2023
© The Author(s) 2024

ABSTRACT

Introduction: Biomarker testing is mandatory for the clinical management of patients with

advanced non-small cell lung cancer (NSCLC). Myriads of technical platforms are now available for biomarker analysis with differences in terms of multiplexing capability, analytical sensitivity, and turnaround time (TAT). We evaluated the technical performance of the diagnostic workflows of 24 representative Italian institutions performing molecular tests on a series of artificial reference specimens built to

A1 Francesco Pepe and Gianluca Russo contributed equally.

A2 **Supplementary Information** The online version
A3 contains supplementary material available at [https://](https://doi.org/10.1007/s40487-023-00252-5)
A4 doi.org/10.1007/s40487-023-00252-5.

A5 F. Pepe · G. Russo · A. Venuta · C. Scimone ·
A6 M. Nacchio · P. Pisapia · M. Russo · C. De Luca ·
A7 L. Palumbo · S. Simonelli · D. Vitale · A. Iaccarino ·
A8 U. Malapelle (✉) · G. Troncone
A9 Department of Public Health, Federico II University
A10 of Naples, Via S. Pansini, 5, 80131 Naples, Italy
A11 e-mail: umberto.malapelle@unina.it

A12 F. Pepe
A13 e-mail: francesco.pepe4@unina.it

A14 G. Russo
A15 e-mail: gianluca.russo@unina.it

A16 A. Venuta
A17 e-mail: alessandro.venuta@unina.it

A18 C. Scimone
A19 e-mail: claudia.scimone@unina.it

A20 M. Nacchio
A21 e-mail: mariantonia.nacchio@unina.it

A22 P. Pisapia
A23 e-mail: pasquale.pisapia@unina.it

mimic routine diagnostic samples.

Methods: Sample sets of eight slides from cell blocks of artificial reference specimens harboring exon 19 *EGFR* (epidermal growth factor receptor) p.E746_AT50del, exon 2 *KRAS* (Kirsten rat sarcoma viral oncogene homologue) p.G12C, *ROS1* (c-ros oncogene 1)-unknown gene fusion, and *MET* (MET proto-oncogene, receptor tyrosine kinase) Δ exon 14 skipping were distributed to each participating institution. Two independent cell block specimens were validated by the University of Naples Federico II before shipment. Methodological and molecular data from reference specimens were annotated.

Results: Overall, a median DNA concentration of 3.3 ng/ μ L (range 0.1–10.0 ng/ μ L) and 13.4 ng/ μ L (range 2.0–45.8 ng/ μ L) were

obtained with automated and manual technical procedures, respectively. RNA concentrations of 5.7 ng/ μ L (range 0.2–11.9 ng/ μ L) and 9.3 ng/ μ L (range 0.5–18.0 ng/ μ L) were also detected. *KRAS* exon 2 p.G12C, *EGFR* exon 19 p.E736_A750del hotspot mutations, and *ROS1* aberrant transcripts were identified in all tested cases, whereas 15 out of 16 (93.7%) centers detected *MET* exon 14 skipping mutation.

Conclusions: Optimized technical workflows are crucial in the decision-making strategy of patients with NSCLC. Artificial reference specimens enable optimization of diagnostic workflows for predictive molecular analysis in routine clinical practice.

Keywords: Lung; Molecular pathology; Tumor biomarker

A24	M. Russo	A43	F. Barbisan
A25	e-mail: maria.russo6@unina.it	A44	e-mail: francesca.barbisan@ospedaliriuniti.marche.it
A26	C. De Luca	A45	C. Chiappetta
A27	e-mail: caterina.deluca@unina.it	A46	Department of Pathology, AOU Policlinico Umberto I, Rome, Italy
A28	L. Palumbo	A47	I, Rome, Italy
A29	e-mail: lucia.palumbo@unina.it	A48	e-mail: caterina.chiappetta@uniroma1.it
A30	S. Simonelli	A49	A. Pernazza
A31	e-mail: saverio.simonelli95@gmail.com	A50	Department of Medico-Surgical Sciences and
A32	D. Vitale	A51	Biotechnologies, Polo Pontino-Sapienza University,
A33	e-mail: dvitale2506@gmail.com	A52	Latina, Italy
A34	A. Iaccarino	A53	e-mail: angelina.pernazza@uniroma1.it
A35	e-mail: antiaccc@hotmail.com	A54	D. Campagna · M. Giordano
A36	G. Troncone	A55	Department of Pathology, San Giovanni-Addolorata
A37	e-mail: giancarlo.troncone@unina.it	A56	Hospital, 00184 Rome, Italy
A38	G. Goteri · F. Barbisan	A57	D. Campagna
A39	Pathological Anatomy Institute, Polytechnic	A58	e-mail: dcampagna@hsangiovanni.roma.it
A40	University of Marche Region, Ancona, Italy	A59	M. Giordano
A41	G. Goteri	A60	e-mail: mgiordano@hsangiovanni.roma.it
A42	e-mail: gaia.goteri@ospedaliriuniti.marche.it		

Key Summary Points

Lung cancer still represents one of the most leading causes of death worldwide. In the last decades, target therapy has radically shifted clinical paradigm for Non-Small Cell Lung Cancer (NSCLC) implementing a clinically approved mandatory testing gene panel able to identify patients with NSCLC administrable with target drugs.

A wide series of diagnostic routine samples (small biopsy, surgical resection, direct smear, cell-block) are diagnostically available for molecular analysis. In this scenario, “scant” diagnostic specimens often represents the only source of nucleic acids for molecular testing. As a consequence, diagnostic testing strategy should be technically optimized in accordance with routinely available biological source.

In this heterogeneous scenario, harmonized procedures may support testing strategies of clinically relevant predictive biomarkers in clinical practice. As regards, in this multicentre trial an artificial reference slide set, mimicking diagnostic samples, was distributed to each participating institutions evaluating concordance rate and inter-laboratory reproducibility.

Among $n=24$ participating institutions, manual and fully automatized analytical procedures highlighted comparable results in terms of technical performance on nucleic acids extraction and molecular analysis. Particularly, DNA based hotspot mutations (*KRAS* (Kirsten Rat Sarcoma Viral Oncogene Homologue) exon 2 p.G12C, *EGFR* (Epidermal Growth Factor Receptor) exon 19 p.E746_A750del) and *ROS1* (c-ros Oncogene 1) aberrant transcripts were successfully detected in all instances whereas *MET* (MET proto-oncogene, receptor tyrosine kinase) exon 14 skipping mutation was identified in 93.7% of institutions approaching this test.

RNA management still represents a hardly managing target in terms of quantity and quality. Optimized pre-analytical and analytical procedures are recommended to improve successful rate of molecular testing on this analyte.

Harmonized ring trials based on artificial samples mimicking diagnostic specimens may represent a key weapon to optimize diagnostic workflow in predictive molecular laboratories.

A61 G. Perrone
 A62 Research Unit of Anatomical Pathology,
 A63 Department of Medicine and Surgery, Università
 A64 Campus Bio-Medico di Roma, Via Alvaro del
 A65 Portillo, 21-00128 Rome, Italy

A66 G. Perrone · G. Sabarese
 A67 Anatomical Pathology Operative Research Unit,
 A68 Fondazione Policlinico Universitario Campus Bio-
 A69 Medico, Via Alvaro del Portillo, 200-00128 Rome, Italy

A70 G. Perrone
 A71 e-mail: g.perrone@policlinicocampus.it

A72 G. Sabarese
 A73 e-mail: g.sabarese@policlinicocampus.it

A74 A. Altimari · G. Tallini
 A75 Molecular Pathology, University of Bologna
 A76 Hospital of Bologna Sant’Orsola-Malpighi
 A77 Polyclinic, Bologna, Italy

A78 A. Altimari
 A79 e-mail: annalisa.altimari@aosp.bo.it

A80 D. de Biase · G. Tallini
 A81 Pharmacy and Biotechnology (FaBiT), Molecular
 A82 Pathology Laboratory, University of Bologna,
 A83 Bologna, Italy

A84 D. de Biase
 A85 e-mail: dario.debiase@unibo.it

A86 G. Tallini
 A87 Department of Medical and Surgical Sciences,
 A88 University of Bologna, Bologna, Italy
 A89 e-mail: giovanni.tallini@ausl.bologna.it

A90 D. Calistri · E. Chiadini · L. Capelli
 A91 Biosciences Laboratory, IRCCS Istituto Romagnolo
 A92 per lo Studio dei Tumori (IRST) “Dino Amadori”,
 A93 47014 Meldola, Italy

INTRODUCTION

Lung cancer still remains one of the leading causes of death worldwide [1]. Over the past two decades, precision medicine has revolutionized the clinical management of patients with advanced lung cancer through the identification of clinically relevant predictive biomarkers [2–4]. In this scenario, an ever-increasing number of predictive biomarkers have emerged as novel targets for molecular analysis [3, 5]. Indeed, biomarkers testing is now highly recommended for the management of patients with non-small cell lung cancer (NSCLC). In this regard, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASCL), and the Association for Molecular Pathology (AMP) have established a panel of “mandatory test genes” [6]. This panel covers DNA -based hot-spot mutations including epidermal growth factor receptor (*EGFR*) and v-Raf murine sarcoma viral oncogene homolog B (*BRAF*), as well as RNA-based aberrant transcripts including anaplastic lymphoma kinase (*ALK*), proto-oncogene 1

(*ROS1*), proto-oncogene tyrosine-protein kinase receptor Ret (*RET*) and *MET* proto-oncogene, receptor tyrosine kinase (*MET*) Δ exon 14 skipping. In addition, *KRAS* (Kirsten rat sarcoma viral oncogene homologue) exon 2 p.G12C mutation has recently been approved as a novel molecular target for the selection of targeted treatments [7–9]. In view of this heterogeneous scenario, next-generation sequencing (NGS) platforms are increasingly being used and recommended in routine clinical practice to comprehensively analyze all clinically approved predictive biomarkers [10, 11].

Although singleplex technologies have a lower mutation detection coverage than multiplex technologies, most Italian molecular diagnostics laboratories still use real-time reverse transcriptase-polymerase chain reaction (RT-PCR)-based assays in their diagnostic workflows [12–14]. In the setting of NSCLC, a wide range of diagnostic specimens are routinely analyzed to detect hot-spot mutations in predictive biomarkers. This procedure is highly complex because each sample type possesses distinct technical features requiring tailored approaches for accurate molecular

A94	D. Calistri	A114	S. Murru
A95	e-mail: daniele.calistri@irst.emr.it	A115	e-mail: stefania.murru@aob.it
A96	E. Chiadini	A116	R. Murgia
A97	e-mail: elisa.chiadini@irst.emr.it	A117	Experimental Medicine Unit, Department of
A98	L. Capelli	A118	Biomedical Sciences, University of Cagliari, 09124
A99	e-mail: laura.capelli@irst.emr.it	A119	Cagliari, Italy
A100	A. Santinelli · A. E. Gulini · E. Pierpaoli	A120	e-mail: murgia.riccardo@gmail.com
A101	Anatomic Pathology Azienda Sanitaria Territoriale	A121	E. G. Rocco · K. Venetis · N. Fusco
A102	Pesaro-Urbino, Pesaro, Italy	A122	Division of Pathology, IEO, European Institute of
A103	A. Santinelli	A123	Oncology IRCCS, Via Giuseppe Ripamonti 435,
A104	e-mail: alfredo.santinelli@ospedalimarchenord.i	A124	20141 Milan, Italy
A105	A. E. Gulini	A125	K. Venetis
A106	e-mail: annaelisa.gulini@ospedalimarchenord.it	A126	e-mail: konstantinos.venetis@ieo.it
A107	E. Pierpaoli	A127	E. G. Rocco · N. Fusco
A108	e-mail: elisa.pierpaoli@ospedalimarchenord.it	A128	Department of Oncology and Hemato-Oncology,
A109	M. Badiali · S. Murru	A129	University of Milan, Via Festa del Perdono 7, 20122
A110	Laboratory of Genetics and Genomics-Pediatric	A130	Milan, Italy
A111	Hospital A.Cao-ASL8, Cagliari, Italy	A131	E. G. Rocco
A112	M. Badiali	A132	e-mail: elena.guerinirocco@ieo.it
A113	e-mail: manuela.badiali@aob.it	A133	N. Fusco
		A134	e-mail: nicola.fusco@ieo.it

analysis. Moreover, a significant proportion of cases rely on limited diagnostic material, an additional complexity that underscores the need for optimized protocols to maximize diagnostic yield [15–17]. Hence, many institutions conducting molecular tests should optimize their own diagnostic workflows for the analysis of clinically relevant predictive biomarkers on the basis of the available diagnostic specimen. Not surprisingly, different technical approaches have been observed across laboratories, giving rise to variations in success rates, turnaround time (TAT), and accuracy of molecular analysis [18]. Undeniably, developing harmonized procedures based on interlaboratory concordance across different institutions represents an open challenge that must be addressed to overcome the technical limitations in routine diagnostic practice. Accordingly, to evaluate the technical performance of these approaches we conducted a multicenter trial involving 24 representative Italian institutions for molecular testing. Each participating institution analyzed artificial reference slides built on engineered cell lines harboring representative clinically relevant mutations in approved biomarkers for patients with NSCLC.

Then, concordance rates and interlaboratory reproducibility were determined by comparing the molecular data reported by each participating institution.

METHODS

Study Design

Each participating institution received a set of reference specimens from the coordinating center. The artificial control was built by mixing four engineered cell lines harboring clinically relevant mutations found in patients with NSCLC (Supplementary Table 1). Before shipment, each cell line was previously analyzed and validated by the laboratories of Federico II University. In brief, nucleic acids were first evaluated on the pellet samples from each cell line (Supplementary Fig. 1). Owing to the challenging management of “scant” RNA samples and heterogeneous technical approaches available for RNA testing, RNA-based biomarkers were additionally tested with an ultra-deep, long-read third-generation NGS platform (ONT-

A135 D. Morotti · A. Gianatti
A136 Pathology Unit and Medical Genetics Laboratory,
A137 Papa Giovanni XXIII Hospital, Bergamo, Italy

A138 D. Morotti
A139 e-mail: dmorotti@asst-pg23.it

A140 A. Gianatti
A141 e-mail: agianatti@asst-pg23.it

A142 D. Furlan
A143 Pathology Unit, Department of Medicine and
A144 Technological Innovation, University of Insubria,
A145 Varese, Italy
A146 e-mail: Daniela.Furlan@uninsubria.it

A147 G. Rossi · L. Melocchi
A148 Department of Anatomical Pathology, Fondazione
A149 Poliambulanza, 25124 Brescia, Italy

A150 G. Rossi
A151 e-mail: giulio.rossi@poliambulanza.it

A152 L. Melocchi
A153 e-mail: laura.melocchi@poliambulanza.it

A154 A. Maffè
A155 Genetics and Molecular Biology Unit, Santa Croce e

A156 Carle Hospital, 12100 Cuneo, Italy
A157 e-mail: maffe.a@ospedale.cuneo.it

A158 P. Francia di Celle
A159 Molecular Pathology, AOU Città della Salute e della
A160 Scienza di Torino, 10126 Turin, Italy
A161 e-mail: pfranciadicelle@cittadellasalute.to.it

A162 T. Venesio
A163 Candiolo Cancer Institute, FPO-IRCCS, 10060
A164 Candiolo, Italy
A165 e-mail: tiziana.venesio@ircc.it

A166 M. Scatolini · E. Grosso
A167 Molecular Oncology Lab, Fondazione Edo ed Elvo
A168 Tempia, Biella, Italy

A169 M. Scatolini
A170 e-mail: maria.scatolini@fondazionetempia.org

A171 E. Grosso
A172 e-mail: enrico.grosso@fondazionetempia.org

A173 S. Orecchia
A174 Pathology Division, S. Antonio and Biagio Hospital,
A175 Alessandria, Italy
A176 e-mail: sorecchia@ospedale.al.it

Nanopore, Oxford UK) (Supplementary Material). Then, cell block specimens were created from each cell line by generating formalin-fixed paraffin-embedded (FFPE) specimens [19]. This hybrid sampling approach, consisting of histological and cytological preparations, proved to be technically feasible and reproducible for this project. Nucleic acid evaluation was also assessed on cell blocks to verify the impact of sample preparation on the integrity of nucleic acids. In addition, molecular analysis was carried out with our own internal diagnostic workflow. Next, two independent cell block specimens were generated from mixed cell lines harboring all the referenced molecular alterations. A representative set of reference specimens from two independent batches were then internally validated before shipment to other institutions. Similarly, nucleic acid purification was carried out with our internal diagnostic workflow. NGS analysis was carried out with both semiautomated (Ion S5 system, Thermo Fisher Scientific) and fully automated NGS platforms (Genexus, Thermo Fisher Scientific). Overall, eight slides (four for DNA and RNA-based

biomarkers, respectively) were distributed to each participating institution. After that, molecular analysis was carried out by each participating institution according to its internal diagnostic workflow. Finally, molecular alterations, DNA/RNA quantity (when technically available), and data reporting were shared with the coordinating center (Fig. 1).

This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Biological material was managed under the authorization of the Department of Public Health at the University of Naples Federico II, Naples. The cell lines used in this study were reference specimens and were not obtained from patients at the institutions. As such, patient informed consent was not applicable for this research. Institutional review board approval for this type of study on artificial samples is not required following the specification reported by The Italian Data Protection Authority and the Helsinki Declaration.

A177	M. Fassan	A199	M. Santacatterina
A178	Department of Medicine-DIMED, University of	A200	e-mail: maria.santacatterina@aulss8.veneto.it
A179	Padua, Padua, Veneto, Italy		
A180	M. Fassan	A201	M. L. Piredda
A181	Veneto Institute of Oncology-IOV-IRCCS, Padua,	A202	e-mail: marialiliana.piredda@aulss8.veneto.it
A182	Italy	A203	M. Riccardi · L. Laurino
A183	e-mail: matteo.fassan@unipd.it	A204	Department of Pathology, Azienda Ulss3
A184	M. Balistreri · E. Zulato	A205	Serenissima, Ospedale dell'Angelo, Venice, Italy
A185	Surgical Pathology Unit, University Hospital of	A206	M. Riccardi
A186	Padua, Padua, Italy	A207	e-mail: Manuela.riccardi@aulss3.veneto.it
A187	M. Balistreri	A208	L. Laurino
A188	e-mail: Mariangela.balistreri@apd.veneto.it	A209	e-mail: licia.laurino@aulss3.veneto.it
A189	E. Zulato	A210	E. Roz
A190	e-mail: Elisabetta.zulato@aopd.veneto.it	A211	Pathology Unit, La Maddalena Clinic for Cancer,
A191	D. Reghellin · E. Lazzari · M. Santacatterina ·	A212	Palermo, Italy
A192	M. L. Piredda	A213	e-mail: roz@lamaddalenanet.it
A193	Department of Pathology, San Bortolo Hospital,	A214	D. Longo · D. P. Romeo · C. Fazzari
A194	Vicenza, Italy	A215	UOSD di Anatomia Patologica dell'Azienda
A195	D. Reghellin	A216	Ospedaliera Papardo, Messina, Italy
A196	e-mail: daniela.reghellin@aulss8.veneto.it	A217	D. Longo
A197	E. Lazzari	A218	e-mail: domenicolongo81@yahoo.it
A198	e-mail: elena.lazzari@aulss8.veneto.it		

Standard Sample Generation and Validation

Cell Culture

Four cell lines harboring clinically relevant molecular alterations found in patients with NSCLC (Supplementary Table 1) were engineered to create artificial sample slides. In brief, HCC827 (Cat# CRL-2868) and H358 (Cat# CRL-5807) cell lines were purchased from the American Type Culture Collection (ATCC); HCC78 (Cat# ACC 563) was purchased from the Leibniz Institute DSMZ—German Collection of Microorganisms and Cell Cultures GmbH; H596 cell line was kindly provided by Dr. Miguel Angel Molina-Vila (Laboratory of Oncology, Pangaea Oncology, Spain). All cell lines were cultured in RPMI-1640 medium (Cat# 30-2001, ATCC) supplemented with 10% of inactivated FBS (fetal bovine serum) (Cat# 30-2020, ATCC), 2 mM glutamine (Cat# TCL012, HiMedia), 100 IU/mL of penicillin (100 IU/mL), and 100 µg/mL of streptomycin (Cat#A001, HiMedia) and maintained within a 5% CO₂ incubator at 37 °C. All cell lines were validated morphologically and routinely tested for the presence of mycoplasma. Every 2–3 days, cells were split

with trypsin–EDTA solution (Cat# TCL139, HiMedia) at a recommended splitting ratio. They were then washed twice in PBS (phosphate buffered saline), harvested via mechanical detachment, and counted in a cell counting chamber (Bürke). In particular, cells were gently detached with a rubber scraper. After harvest, all cell aliquots were washed in PBS once; then 10 µL of cell suspension was placed in a cell count chamber; afterwards, cells were counted in each of the three large squares. At the end of the procedure, the average number of viable cells and overall cell concentration were calculated according to the following standardized formula:

$$[\text{Cells/ml}] = \left[\frac{\sum \text{cells counted in 3 large square}}{3} \right] \times (\text{dilution factor}) \times 1 \times 10^4$$

DNA and RNA Extraction

DNA was isolated and purified from HCC827 (exon 19 *EGFR* p.E746_AT50del), H358 (exon 2 *KRAS* p.G12C), and cell blocks of mixed cell lines with the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. In brief, after nucleic acid extraction and purification, DNA was resuspended at –80 °C until molecular analysis.

A219	D. P. Romeo	A240	A. D. Prjibelski · D. Shafranskaya
A220	e-mail: romeopetra@libero.it	A241	Center for Algorithmic Biotechnology, Institute of
A221	C. Fazzari	A242	Translational Biomedicine, St. Petersburg State
A222	e-mail: cfazzari@hotmail.it	A243	University, St. Petersburg, Russia
A223	A. Moreno-Manuel	A244	A. D. Prjibelski
A224	Molecular Oncology Laboratory, Fundación	A245	e-mail: andrewprzh@gmail.com
A225	Investigación Hospital General Universitario de	A246	D. Shafranskaya
A226	Valencia, 46014 Valencia, Spain	A247	e-mail: dariashafranskaya@gmail.com
A227	A. Moreno-Manuel	A248	L. Righi · A. Listi
A228	TRIAL Mixed Unit, Centro Investigación Príncipe	A249	Department of Oncology, San Luigi Hospital,
A229	Felipe-Fundación Investigación Hospital General	A250	University of Turin, Orbassano, TO, Italy
A230	Universitario de Valencia, 46014 Valencia, Spain	A251	L. Righi
A231	A. Moreno-Manuel	A252	e-mail: luisella.righi@unito.it
A232	Centro de Investigación Biomédica en Red Cáncer,	A253	A. Listi
A233	CIBERONC, 28029 Madrid, Spain	A254	e-mail: angela.listi@unito.it
A234	e-mail: andrea.morenomanuel@gmail.com		
A235	G. D. Puglia		
A236	Institute for Agricultural and Forest Systems in the		
A237	Mediterranean, National Research Council		
A238	(ISAFOM-CNR), 95128 Catania, Italy		
A239	e-mail: giuseppediego.puglia@cnr.it		




Fig. 1 Schematic representation of study design. Briefly, after internal validation of standard reference sample at University of Naples Federico II, a set of eight slides were distributed to each center. Here, own diagnostic workflow (from nucleic acid extraction to molecular data

interpretation) was applied. Data were shared with the coordinating center. *MET* MET proto-oncogene, receptor tyrosine kinase, *ROS1* c-ros oncogene 1, *SLC34A2* solute carrier family 34 member 2

RNA was instead extracted from HCC78 (*ROS1*-unknown gene fusion), H596 (*MET* Δ exon 14 skipping), and cell blocks of mixed cell lines by using the All-prep DNA/RNA mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions; then, RNA extracts were resuspended in 30 μL of nuclease-free water. The quantity and quality of nucleic acids were assessed with an automated electrophoresis system (TapeStation 4200, Agilent Technologies, Santa Clara, California, USA).

Molecular Analysis

After evaluation of nucleic acids, SiReTM and SiRe fusion panels were applied to Ion S5TM plus (Thermo Fisher Scientific) to assess the mutational status on the first cell block according to the manufacturer's procedures [20–22].

An independent series of eight slides from a second cell block was analyzed on a fully automated NGS platform (Genexus, Thermo Fisher Scientific) with the OncoPrint Precision Assay (OPA) panel (Thermo Fisher Scientific); this assay covers all the actionable genes in patients with NSCLC.

RESULTS

Standard Sample Generation and Validation

Nucleic Acid Extraction

Overall, DNA quantification highlighted comparable levels between cell pellet (HCC827 8.9 ng/μL, H358 115.0 ng/μL) and cell block (HCC827 7.5 ng/μL, H358 145.0 ng/μL) preparations from corresponding cell lines. In addition, the DNA integrity number (DIN) of cell pellet preparations was similar to those of HCC827-derived and H358-derived cell block samples (6.9 and 7.9 vs 6.9 and 8.9, respectively). RNA evaluation from HCC78 and H596 samples on TapeStation 4200 (Agilent) revealed that cell block sampling, but not cell pellet preparations, affected RNA yield (HCC78, 12.5 ng/μL vs 15.3 ng/μL; H596, 6.3 ng/μL vs 9.5 ng/μL, respectively) and index fragmentation (2.6 vs 4.0 and 1.6 vs 3.9). Hence, nucleic acid extraction and qualification of cell block specimens from mixed engineered cell lines were conducted. As expected, DNA and RNA

yields were consistent with previous data: [(DNA 8.2 ng/ μ L, DIN 2.0; RNA 37.2 ng/ μ L, RIN 1.0) block 1; (DNA 6.1 ng/ μ L, DIN 2.9; RNA 25.4 ng/ μ L, RIN 1.0) block 2] (Supplementary Fig. 2).

Molecular Analysis

NGS analysis was successfully carried out in all instances. Briefly, adequate technical parameters of DNA and RNA samples were obtained from semiautomated NGS systems [DNA sample: number of reads 566,693, mean read length 146, number of mapped reads 565,956, percent reads on target 99.6%, average reads per amplicon 13,415, uniformity of amplicon coverage 97.6%]; RNA sample: number of reads 365,350, mean read length 117, mapped reads for *SLC34A2(4)-OS1(32)* 45,651, mapped reads for *MET* Δ exon 14 3066]. Likewise, adequate parameters of DNA and RNA samples were obtained from fully automated NGS systems [DNA sample: number of reads 1,966,288, mean read length 97, number of mapped reads 1,951,334, percent reads on target 95.3%, average reads per amplicon 6828, uniformity of amplicon coverage 95.8%]; RNA sample: number of reads 1,591,464, mean read length 101, mapped reads for *SLC34A2(4)-OS1(32)* 3327, mapped reads for *MET* Δ exon 14 349] (Table 1).

NGS analysis on two independent cell blocks from mixed engineered cell lines confirmed all the molecular alterations found in single-cell populations, showing no differences between semiautomated and fully automated NGS platforms (Supplementary Fig. 3A, 3B).

Standard Sample Analysis

Overall, series of eight reference 5- μ m slide sets, generated from previously validated cell block samples, were successfully shared with all participating institutions. Molecular results were shared with the coordinating institution within 30 working days, as recommended by the study protocol. Regarding the geographical distribution of the centers, 14 out of 24 (58.4%) were located in Northern Italy, 5 out of 24 (20.8%) in Central Italy, and 5 out of 24 (20.8%) in Southern Italy. Only one participating institution (ID#22) (4.2%) was unable to perform the

molecular analysis and to convey the results to the coordinating center.

Regarding nucleic acids extraction, 21 out of 23 (91.3%) centers successfully carried out DNA purification, whereas 17 out of 23 (73.9%) participating centers successfully performed RNA extraction. Moreover, DNA and RNA purification was performed with manual strategies in 9 out of 21 (42.8%) and in 6 out of 17 (35.3%) institutions and with automated platforms in 12 out of 21 (57.2%) and in 11 out of 17 (64.7%) institutions. In a single case, neither DNA nor RNA purification was performed (ID#23). Owing to some technical issues, DNA purification failed in one automated test-based center. Furthermore, DNA and RNA quantification was performed by 20 out of 21 (95.2%) and 15 out of 17 (88.2%) participating institutions. In particular, a median DNA concentration of 3.3 ng/ μ L (range 0.1–10.0 ng/ μ L) was inspected with automated systems, whereas a median of 13.4 ng/ μ L (range 2.0–45.8 ng/ μ L) was inspected with manual procedures. Moreover, RNA concentrations of 5.7 ng/ μ L (range 0.2–11.9 ng/ μ L) and 9.3 ng/ μ L (range 0.5–18.0 ng/ μ L) were detected in the same settings (Table 2, Fig. 2).

As shown in Fig. 2, manual procedures yielded higher concentrations than automated procedures. Center ID#20 yielded higher DNA concentrations probably because it used all the available input slides for DNA isolation. Moreover, a comparative analysis between the DNA and RNA yields obtained either by automated or manual procedures suggested once more that manual extraction yields higher DNA concentrations ($p = 0.038$) than automated systems (Table 3).

However, no statistically significant difference was observed for RNA extraction (Table 4).

Overall, DNA-based biomarker analysis was successfully carried out by 22 out of 23 (95.6%) participating institutions, whereas RNA-based molecular analysis was achieved in 18 out of 19 (94.7%) centers equipped with all the necessary technical support; of note, RNA molecular analysis was successfully carried by ID#13 by using a fully automated platform without previous RNA extraction.

Table 1 Validation step

Sample	Platform	Reads	Mean read length	Number of mapped reads	Percent reads on target	Average reads per amplicon	Uniformity of amplicon coverage	Total mapped fusion panel reads
CB_1_DNA	S5plus	566,693	146	565,956	99.6%	13,415	97.6%	NA
CB_1_RNA	S5plus	365,350	117	NA	NA	NA	NA	128,762
CB_2_DNA	GENEXUS	1,966,288	97	1,951,334	95.3%	6828	95.8%	NA
CB_2_RNA	GENEXUS	1,591,464	101	NA	NA	NA	NA	NA

Technical parameters from NGS analysis performed on two different platforms at University of Naples Federico II
CB cell block, *NA* not available

Testing Strategies and Molecular Analysis

For the molecular analyses, participating centers adopted their own routine diagnostic method. For DNA-related biomarker testing, NGS, RT-PCR, and MassArray-based systems were employed in 14 out of 22 (63.6%), 5 out of 22 (22.8%), and 1 out of 22 (4.6%) institutions, respectively. Moreover, DNA-based biomarkers were tested with NGS plus RT-PCR platforms and pyrosequencing plus RT-PCR in two institutions (ID#8 and ID#20, respectively). Among the centers that adopted GS, one institution (ID#6) used two different NGS systems (hybridization and amplicon-based platforms) to validate the molecular results, whereas another institution (ID#5) used a commercially available NGS panel plus a customized NGS assay. Overall, hybridization-based and amplicon-based NGS systems were adopted in 12 out of 14 (85.7%) and 2 out of 14 (14.3%) participating centers, respectively. Among the institutions that implemented RT-PCR-based systems, 3 out of 5 (60.0%) adopted a semiautomated lyophilized system, whereas 2 out of 5 (40.0%) adopted a fully automated system. Concerning RNA-based biomarker testing, 7 out of 18 (38.9%) and 9 out of 18 (50.0%) participating institutions reported using NGS-based and RT-PCR-based solutions, respectively. Interestingly, two centers adopted a hybridization-based NGS system plus a semiautomated RT-PCR platform either to confirm their molecular results (ID#18) or to repeat their molecular analysis after failing with NGS (ID#17) (11.2%). As with DNA-based

biomarkers, one participating laboratory employed two independent NGS systems (hybridization and amplicon-based platforms) to carry out RNA-based molecular analysis (ID#6). Overall, hybridization-based (5 out of 7, 71.4%) and amplicon-based strategies (2 out of 7, 28.6%) were assessed in the NGS group. Moreover, 2 out of 9 (22.2%) and 7 out of 9 (77.8%) fully automated and semiautomated automated lyophilized RT-PCR systems were reported, respectively (Table 5).

Data Analysis

Overall, *KRAS* exon 2 p.G12C and *EGFR* exon 19 p.E746_A750del hotspot mutations were successfully detected by all participating institutions. Interestingly, for the detection of *KRAS* exon 2 p.G12C, 14 out of 21 (66.6%), 4 out of 21 (19.0%), 1 out of 21 (4.8%), 1 out of 21 (4.8%), and 1 out of 21 (4.8%) institutions adopted NGS, RT-PCR, NGS plus RT-PCR, MassArray, and pyrosequencing systems, respectively; instead, for the detection of *EGFR* exon 19 p.E746_A750del, 14 out of 22 (63.7%), 6 out of 22 (27.3%), 1 out of 22 (4.5%), and 1 out of 22 (4.5%) adopted NGS, RT-PCR, NGS plus RT-PCR, and MassArray systems, respectively (Fig. 3). In this regard, the sequencing platforms yielded median mutant allelic fraction (MAF) values of 29.5% (range 14.0–52.0%) and 80.3% (range 61.0–92.0%) for *KRAS* p.G12C and *EGFR* p.E746_A750del mutations, respectively. Similarly, RT-PCR-based technologies yielded a median Ct of 29.9 (range 27.4–35.1)

Table 2 List of DNA and RNA extraction kits used by participating institutions and matched nucleic acids quantification data

Center ID	DNA extraction kit	DNA quantification Yes/No	DNA ng/ μ L	RNA extraction kit	RNA quantification Yes/No	RNA ng/ μ L
1	Qiaamp DNA Mini kit (Qiagen)	Yes	3.2	MagCore Total RNA FFPE One-Step Kit (Diatech Pharmacogenetics)	Yes	0.5
2	RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE. ThermoFisher Scientific	Yes	2.1	RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE. ThermoFisher Scientific	Yes	7.8
3	EasyPGX Extraction Kit	No	N/A	N/A	No RNA extracted	N/A
4	QIAamp DNA FFPE Tissue Kit	Yes	2.5	High Pure FFPE RNA Isolation Kit	Yes	0.6
5	Maxwell RSC DNA FFPE Kit (Promega)	Yes	1.5	Maxwell RSC RNA FFPE Kit (Promega)	Yes	10.0
6	Maxwell RSC DNA FFPE kit_Promega	Yes	1.6	Maxwell RSC RNA FFPE kit_Promega	Yes	11.9
7	MagCore Genomic DNA FFPE One-Step Kit	Yes	1.5	MagCore Total RNA FFPE One-Step Kit	No	N/A
8	Maxwell CSC DNA FFPE kit (estrazione di acidi nucleici totali)	Yes	2.0	Maxwell CSC DNA FFPE kit (estrazione di acidi nucleici totali)	Yes	2.9
9	QIACUBE	No DNA extracted	N/A	QIACUBE	Yes	8.8
10	Promega Maxwell RSC DNA FFPE kit	Yes	0.9	Promega Maxwell RSC RNA FFPE kit	Yes	6.3
11	QIAamp DNA FFPE Tissue Kit	Yes	8.1	N/A	No RNA extracted	N/A
12	Maxwell CSC System Promega. kit Maxwell CSC RNA FFPE	Yes	10.0	Maxwell CSC System Promega. kit Maxwell CSC RNA FFPE	Yes	7.6
13	MagCore Genomic DNA FFPE One-Step Kit	Yes	0.4	N/A	No RNA extracted	N/A
14	Maxwell RSC DNA FFPE Kit (Promega)	Yes	9.3	Maxwell RSC RNA FFPE Kit (Promega)	Yes	9.0
15	Maxwell RSC DNA FFPE Kit (Promega)	Yes	5.4	Maxwell RSC RNA FFPE Kit (Promega)	Yes	0.4

Table 2 continued

Center ID	DNA extraction kit	DNA quantification Yes/No	DNA ng/ μ L	RNA extraction kit	RNA quantification Yes/No	RNA ng/ μ L
16	GeneReadDNA FFPE KIT QIAGEN	Yes	27.0	Roche FFPET RNA Isolation Kit	Yes	12.5
17	Qiagen QIAamp DNA FFPE Advanced UNG Kit	Yes	9.0	Qiagen RNeasy FFPE kit	Yes	18.0
18	MaGCore Nucleic Acid Extraction Kit	Yes	0.4	MaGCore Nucleic Acid Extraction Kit	Yes	0.2
19	QIAamp DNA FFPE Tissue Kit QIAGEN	Yes	9.7	RNA: Rneasy FFPE Kit QIAGEN	No	N/A
20	Mini amp kit FFPE qiagen	Yes	45.8	N/A	No RNA extracted	N/A
21	Maxwell RSC FFPE Plus DNA kit	Yes	0.1	N/A	No RNA extracted	N/A
22	–	–	–	–	–	–
23	N/D	No	N/A	N/D	No	N/A
24	MagCore [®] Genomic DNA FFPE One-Step Kit (Codice cartuccia 405)	Yes	6.5	High Pure FFPET kit RNA Isolation Kit-Roche [®]	Yes	7.8

N/A not assessed, N/D not defined, FFPE formalin-fixed paraffin-embedded

and 26.0 (range 24.9–27.5) for the same genetic alterations. For RNA-related molecular results, 15 out of 16 (93.7%) participating institutions detected *MET* exon 14 skipping mutation, whereas all institutions detected *ROS1* gene fusion using RT-PCR. In addition, 13 out of 18 (72.2%) centers successfully detected both *ROS1* rearrangements and *MET* Δ exon 14 skipping alterations. Overall, 7 out of 16 (43.8%), 8 out of 16 (50.0%), 1 out of 16 (6.2%), 5 out of 15 (33.3%), 8 out of 15 (53.4%), and 2 out of 15 (13.3%) institutions adopted NGS, RT-PCR, and NGS plus RT-PCR systems for the detection of *ROS1* aberrant transcript and *MET* Δ exon 14 skipping molecular alterations (Fig. 4). In addition, in ID#17, RT-PCR was used after NGS failed to detect *MET* Δ exon 14 skipping molecular alterations. In this regard, NGS

platforms generated median readcounts of 48,647.6 (range 84.0–138,166.0) and 2981.2 (range 37.0–8340.0) for *ROS1* rearrangement and *MET* exon 14 skipping, respectively. Similarly, RT-PCR based systems generated a median Ct of 28.6 (range 25.5–31.1) and 31.8 (range 27.8–35.0) for *ROS1* rearrangement and *MET* Δ exon 14 skipping alterations, respectively. Moreover, 13 out of 18 (72.2%) institutions also evaluated *MET* Δ exon 14 skipping molecular alteration on DNA samples. Interestingly, 2 out of 13 (15.4%) suggested DNA-based molecular analysis as an alternative to the RNA testing strategy (Fig. 5). Of note, 11 centers successfully detected *MET* Δ exon 14 skipping molecular alteration using both DNA- and RNA-based detection strategies. In a single case (ID#11), *ROS1* rearrangement was successfully detected




Fig. 2 DNA and RNA concentration by participating center. Scatterplots showing **a** DNA and **b** RNA concentration obtained by each participating center, colored by the extraction method (red, automatic procedure; blue, manual procedure)

Table 3 DNA concentration according to the extraction procedure (automatic or manual)

DNA	Automatic (<i>N</i> = 12)	Manual (<i>N</i> = 7)	Total (<i>N</i> = 19)	<i>p</i> value
Median	1.565	8.060	2.490	0.038
Q1, Q3	0.739, 5.675	2.855, 9.355	1.490, 8.530	
Range	0.050–0.000	2.049–27.000	0.050–27.000	

Table shows median, quartile 1, quartile 3, and range of each category. *p* value was obtained using Mann–Whitney *U* test *Q1* quartile 1, *Q3* quartile 3, *N* number

Table 4 RNA concentration according to the extraction procedure (automatic or manual)

RNA	Automatic (<i>N</i> = 10)	Manual (<i>N</i> = 5)	Total (<i>N</i> = 15)	<i>p</i> value
Median	6.950	7.800	7.800	0.244
Q1, Q3	1.080, 8.950	7.800, 12.500	1.700, 9.500	
Range	0.200–11.900	0.550–18.000	0.200–18.000	

Table shows median, quartile 1, quartile 3, and range of each category. *p* value was obtained using Mann–Whitney *U* test *Q1* quartile 1, *Q3* quartile 3, *N* number

without previous RNA-based molecular analysis. A list of additional molecular alterations reported by the participating institutions is provided in Supplementary Table 2.

DISCUSSION

Today, biomarker testing plays a pivotal role in guiding therapy choices for patients with solid tumors, including NSCLC [23]. However, two

Table 5 List of technical platforms and molecular results for each participating institution

Center ID	DNA analysis	DNA mutations	MAF% or Ct	RNA analysis	RNA mutations	Reads count or Ct
1	NGS	<i>KRAS</i> p.G12C <i>EGFR</i> p.E746_A750del <i>MET</i> c.3082 + 1G > T	36.3% 72.2% 22.8%	NGS	<i>ROS1</i> SLC34A2- <i>ROS1</i> S4:R32	3277 reads
2	NGS	<i>KRAS</i> p.G12C <i>EGFR</i> p.E746_A750del <i>MET</i> c.3082 + 1G > T	18.0% 86.5% 5.6%	RealTime	<i>MET</i> Δ ex14 <i>ROS1</i> SLC34A2- <i>ROS1</i> S4:R32	31.9 Ct 29.8 Ct
3	RealTime	<i>EGFR</i> Del Ex19	27.5 Ct	N/A	N/A	N/A
4	NGS	<i>KRAS</i> p.G12C <i>EGFR</i> p.E746_A750del <i>MET</i> c.3082 + 1G > T	33.3% 84.4% 28.1%	RealTime	<i>MET</i> Δ ex14 <i>ROS1</i> SLC34A2- <i>ROS1</i> S4:R32	32.0 Ct 27.6 Ct
5	NGS	<i>KRAS</i> p.G12C <i>EGFR</i> p.E746_A750del <i>MET</i> c.3082 + 1G > T	17.8% 92.0% 6.4%	NGS	<i>ROS1</i> SLC34A2- <i>ROS1</i> S4:R32	74,380 reads
6	NGS	<i>KRAS</i> p.G12C <i>EGFR</i> p.E746_A750del <i>MET</i> c.3082 + 1G > T	15.0% 88.0% 8.0%	NGS	<i>MET</i> Δ ex14 <i>ROS1</i> SLC34A2- <i>ROS1</i> S4:R32	8340 reads 138,166 reads
7	NGS	<i>KRAS</i> p.G12C <i>EGFR</i> p.E746_A750del <i>MET</i> c.3082 + 1G > T	50.3% 85.8% 8.1%	RealTime	<i>MET</i> Δ ex14 <i>ROS1</i> SLC34A2- <i>ROS1</i> S4:R32	32.5 Ct 27.9 Ct
8	NGS/ RealTime	<i>KRAS</i> p.G12C <i>EGFR</i> p.E746_A750del	42.9%/35.2 Ct 72.4%/26.8 Ct	NGS	<i>MET</i> Δ ex14 <i>ROS1</i> SLC34A2- <i>ROS1</i> S4:R32	468 reads 6101 reads

Table 5 continued

Center ID	DNA analysis	DNA mutations	MAF% or Ct	RNA analysis	RNA mutations	Reads count or Ct
9	N/A	N/A	N/A	RealTime	Analysis failed	Analysis failed
10	NGS	<i>KRAS</i> p.G12C	14.0%	NGS	<i>MET</i> Δ ex14	5966 reads
		<i>EGFR</i>	85.0%		<i>ROS1</i> SLC34A2- <i>ROS1</i>	96,702 reads
		p.E746_A750del	9.0%		S4:R32	
		<i>MET</i>				
		c.3082 + 1G > T				
11	NGS	<i>KRAS</i> p.G12C	16.2%	N/A	N/A	N/A
		<i>EGFR</i>	78.5%			
		p.E746_A750del	21.0%			
		<i>ROS1</i> SLC34A2- <i>ROS1</i>				
12	NGS	<i>KRAS</i> p.G12C	37.0%	NGS	<i>MET</i> Δ ex14	37 reads
		<i>EGFR</i>	73.6%		<i>ROS1</i> SLC34A2- <i>ROS1</i>	84 reads
		p.E746_A750del	24.2%		S4:R32	
		<i>MET</i>				
		c.3082 + 1G > T				
13	RealTime	<i>KRAS</i> p.G12C	29.1 Ct	RealTime	<i>MET</i> Δ ex14	30.5 Ct
		<i>EGFR</i> Del Ex19	25.5 Ct		<i>ROS1</i> SLC34A2- <i>ROS1</i>	31.1 Ct
					S4:R32	
14	RealTime	<i>KRAS</i> p.G12C	27.4 Ct	RealTime	<i>ROS1</i> SLC34A2- <i>ROS1</i>	29.7 Ct
		<i>EGFR</i> Del Ex19	24.9 Ct		S4:R32	
15	NGS	<i>KRAS</i> p.G12C	15.7%	NGS	<i>MET</i> Δ ex14	95 reads
		<i>EGFR</i>	84.3%		<i>ROS1</i> SLC34A2- <i>ROS1</i>	21,823 reads
		p.E746_A750del	6.4%		S4:R32	
		<i>MET</i>				
		c.3082 + 1G > T				
16	Mass array	<i>KRAS</i> p.G12C	45.0%	RealTime	<i>MET</i> Δ ex14	35.0 Ct
		<i>EGFR</i>	61.0%			
		p.E746_A750del				
17	NGS	<i>KRAS</i> p.G12C	37.6%	NGS/ RealTime	<i>MET</i> Δ ex14	33.3 Ct
		<i>EGFR</i>	73.6%			
		p.E746_A750del	22.1%			
		<i>MET</i>				
		c.3082 + 1G > T				

Table 5 continued

Center ID	DNA analysis	DNA mutations	MAF% or Ct	RNA analysis	RNA mutations	Reads count or Ct
18	NGS	<i>KRAS</i> p.G12C	52.0%	NGS/ RealTime	<i>MET</i> Δ ex14	30.5 Ct
		<i>EGFR</i>	86.0%		<i>ROS1</i> SLC34A2- <i>ROS1</i>	29.0 Ct
		p.E746_A750del	7.0%		S4:R32	
		<i>MET</i> c.3082 + 1G > T				
19	NGS	<i>KRAS</i> p.G12C	35.4%	RealTime	<i>MET</i> Δ ex14	33.4 Ct
		<i>EGFR</i>	72.0%		<i>ROS1</i> SLC34A2- <i>ROS1</i>	29.1 Ct
		p.E746_A750del	24.3%		S4:R32	
		<i>MET</i> c.3082 + 1G > T				
20	PyroSeq/ RealTime	<i>KRAS</i> p.G12C	20.0%	N/A	N/A	N/A
		<i>EGFR</i> Del Ex19	N/D			
21	RealTime	<i>KRAS</i> p.G12C	27.8 Ct	N/A	N/A	N/A
		<i>EGFR</i> Del Ex19	25.2 Ct			
22	–	–	–	–	–	–
23	RealTime	<i>KRAS</i> p.G12C	N/D	RealTime	<i>MET</i> Δ ex14	27.8 Ct
		<i>EGFR</i> Del Ex19	N/D		<i>ROS1</i> SLC34A2- <i>ROS1</i>	25.5 Ct
24	NGS	<i>KRAS</i> p.G12C	14.7%	RealTime	<i>MET</i> Δ ex14	30.8 Ct
		<i>EGFR</i>	89.7%		<i>ROS1</i> SLC34A2- <i>ROS1</i>	27.7 Ct
		p.E746_A750del	10.3%		S4:R32	
		<i>MET</i> c.3082 + 1G > T				

Ct cycle threshold, *KRAS* Kirsten rat sarcoma virus, *MAF* minor allele frequency, *MET* mesenchymal epithelial transition factor, *N/A* not assessed, *N/D* not defined, *NGS* next-generation sequencing, *RET* rearranged during transfection, *ROS1* c-ros oncogene 1

main critical issues hinder the widespread adoption of biomarker testing in routine clinical practice. A primary limitation is that in a substantial number of advanced cases of NSCLC, the diagnostic material is oftentimes insufficient for molecular testing. A secondary but equally limiting issue is the considerable heterogeneity among laboratories in managing the pre-analytical steps. This factor contributes to reducing even further the already scarce

availability of diagnostic samples for the identification of DNA and RNA-based biomarkers [25, 26]. In this scenario, harmonization of the analytical procedures is key to achieving timely and accurate analysis of clinically relevant biomarkers starting from very challenging diagnostic specimens [27]. In the present study, we strove to evaluate interlaboratory performance and reproducibility between 24 Italian laboratories by using a standard reference




Fig. 3 Pie charts showing the different techniques used for analysis of DNA **a** *KRAS* and **b** *EGFR* hotspot mutations. *NGS* next-generation sequencing, *PyroSeq* pyrosequencing,

KRAS Kirsten rat sarcoma viral oncogene homologue, *EGFR* epidermal growth factor receptor




Fig. 4 Pie charts showing the different techniques used for analysis of RNA **a** *ROS1* gene fusions and **b** *MET* exon 14 skipping. *NGS* next-generation sequencing, *MET* MET

proto-oncogene, receptor tyrosine kinase, *ROS1* c-ros oncogene 1




Fig. 5 Bar chart showing the percentage of cases in which *MET* exon 14 skipping was detected using DNA-based technologies, RNA-based technologies, or both. *MET* MET proto-oncogene, receptor tyrosine kinase

specimen built ad hoc for this study. Overall, we observed no sharp distinction between the molecular testing approaches employed by the various participating institutions. In fact, RNA analysis was feasible in 19 out of 23 institutions, albeit technically equipped for DNA-based molecular testing. However, RNA-based molecular analyses appeared to be quite complex owing to RNA pre-analytical and analytical procedures, suggesting that well-trained personnel and technically equipped laboratories are indispensable to optimize the application of molecular testing in routine clinical practice.

As regards, purification of nucleic acids is another crucial factor to ensure accurate identification of predictive biomarkers [26]. Of note, we observed that a comparable number of institutions adopted manual and automated technical procedures for DNA and RNA purification. Regarding extraction efficiency, our analysis revealed a statistically significant difference between manual and automated extraction procedures for DNA-based biomarkers ($p = 0.038$) but not for RNA-based biomarkers. These findings highlight that scant and not easily manageable samples from diagnostic routine practice could benefit from manual procedures built on specific technical

parameters. Moreover, we observed no statistically significant results for RNA-derived biomarkers owing to the low and non-comparable number of institutions adopting manual and automated procedures in the RNA analysis scenario. Interestingly, DNA purification failed in one institution adopting an automated purification platform. Accordingly, some studies suggest that establishing tailored pre-analytical diagnostic procedures for challenging samples can improve sample adequacy for molecular testing [28].

Given the critical limitations of NSCLC diagnostic specimens, we advance the hypothesis that automated extraction platforms seem less adaptable to scant diagnostic sample. Indeed, our findings evidenced that manual extraction procedures improved DNA/RNA yields from scant diagnostic specimens (13.4 vs 3.3 ng/ μ L DNA, 9.3 vs 5.7 ng/ μ L RNA).

Regarding the types of technical platforms employed, NGS and RT-PCR platforms were most commonly used (63.6% vs 22.8% and 56.2–60.0%) for DNA and RNA-derived biomarkers, respectively. In terms of reference range, all RT-PCR based institutions (6 out of 22) named *EGFR* deletion “delex19” in accordance with RT-PCR proprietary software assignments. To date, identifying and evaluating the different types of *EGFR* clinically relevant mutations is crucial as clinical responses to *EGFR* tyrosine kinase inhibitors may vary depending on the type of activating mutation [29].

Another case in point is the recent approval of *KRAS* exon 2 *p.G12C* hotspot mutation. Indeed, patients harboring this mutation can now benefit from *p.G12C*-targeted therapies [30]. However, because of the ever-increasing number of predictive biomarkers, some technologies may present some limitations owing to the small-sized input material available in most NSCLC cases. For instance, the RT-PCR testing strategy may fail because of the sequential analytical procedures required to cover all the clinically approved biomarkers. For this reason, in some cases, a “selection” of biomarker tests is necessary to circumvent the issue of inadequate amounts of nucleic acids, oftentimes too scarce to cover all the diagnostically relevant genes

[24]. In this context, the implementation of NGS platforms has proven useful to overcome these limitations as they can analyze all drug-gable tumor-specific mutations simultaneously. Remarkably, another major advantage of this high-throughput sequencing technology is that it can successfully analyze molecular biomarkers starting from very low concentrations of nucleic acids, as demonstrated in this study (ID#9). Interestingly, 14 out of 23 participating institutions adopting NGS platforms identified molecular alterations that were not included in this project. Despite such outstanding analytical performance, some cases were not adequately profiled. Specifically, these cases were characterized by limited yields of tumor-derived nucleic acids (ID#11). Thus, an integrated diagnostic approach combining RT-PCR and NGS platforms may represent a robust technical strategy to identify molecular targets in scant diagnostic specimens [10]. Accordingly, orthogonal technologies are required as confirmatory testing approaches for samples characterized by a low percentage of tumor cells [31]. Similarly, integrating biological matrices in diagnostic algorithms may help to overcome clinical limitations (insufficient diagnostic material) and analytical issues (low sensitive molecular testing platforms and critical pre-analytical managing steps) [32]. Regarding *MET* Δ exon 14 skipping mutations, studies have shown that both DNA- and RNA-based approaches can be used to detect these variants in patients who could benefit from selective *MET* inhibitors [33, 34]. Of note, in ID#1 and in five other institutions, *MET* Δ exon 14 skipping was successfully detected in DNA input material. On the other hand, RNA was not sequenced because of the lack of sufficient material; interestingly, the institutions that used both DNA- and RNA-based approaches reported no statistically significant difference in *MET* detection rates (Fig. 5 and Table 5). Of note, in line with Davies et al.'s results, our findings suggest implementing DNA as input starting material when RNA procedures fail owing to poor-quality RNA. In addition, we found no statistically significant differences in *MET* detection rates between NGS and RTqPCR. This finding should, however, be further confirmed in larger studies,

as it could have derived from the limited sample size.

CONCLUSION

Although a limitation of this study is the partial representation of clinically approved biomarkers for the management of patients with NSCLC, it does provide a brief but informative overview of the molecular testing strategies implemented in Italy. Notably, our present findings suggest that optimizing diagnostic algorithms by integrating technical platforms for molecular testing may improve the success rates of molecular analysis. Moreover, given that molecular testing procedures may vary across different laboratories, this study also suggests that the implementation of artificial controls in harmonized ring trials could be a valid tool for evaluating the technical efficiency of diagnostic workflows across molecular diagnostic laboratories. Indeed, our engineered cell lines harboring known genomic alterations could be instrumental in validating an ever-growing number of available molecular platforms both on DNA-based and RNA-based biomarkers. Finally, further investigation is warranted to evaluate how pre-analytical and analytical factors, as well as data analysis, can influence the molecular analysis of diagnostic routine samples.

Author Contributions. Conceptualization: Francesco Pepe, Gianluca Russo, Giancarlo Troncone and Umberto Malapelle. Methodology: Francesco Pepe, Gianluca Russo, Alessandro Venuta, Claudia Scimone, Mariantonia Nacchio, Pasquale Pisapia, Gaia Goteri, Francesca Barbisan, Caterina Chiappetta, Angelina Pernazza, Domenico Campagna, Marco Giordano, Giuseppe Perrone, Giovanna Sabarese, Annalisa Altimari, Dario de Biase, Giovanni Tallini, Daniele Calistri, Elisa Chiadini, Laura Capelli, Alfredo Santinelli, Anna Elisa Gulini, Elisa Pierpaoli, Manuela Badiali, Stefania Murru, Riccardo Murgia, Elena Guerini Rocco, Konstantinos Venetis, Nicola Fusco, Denise Morotti, Andrea Gianatti, Daniela Furlan, Giulio Rossi,

Laura Melocchi, Maria Russo, Caterina De Luca, Lucia Palumbo, Saverio Simonelli, Antonella Maffè, Paola Francia di Celle, Tiziana Venesio, Maria Scatolini, Enrico Grosso, Sara Orecchia, Matteo Fassan, Mariangela Balistreri, Elisabetta Zulato, Daniela Reghellin, Elena Lazzari, Maria Santacatterina, Maria Liliana Piredda, Manuela Riccardi, Licia Laurino, Elena Roz, Domenico Longo, Daniela Petronilla Romeo, Carmine Fazzari, Andrea Moreno-Manuel, Giuseppe Diego Puglia, Andrey D. Prjibelski, Daria Shafranskaya, Luisella Righi, Angela Listi, Domenico Vitale, Antonino Iaccarino, Umberto Malapelle, Giancarlo Troncone. Software: Francesco Pepe, Gianluca Russo and Andrea Moreno Manuel. Validation: All the authors. Formal analysis: All the authors. Data Curation: Francesco Pepe, Gianluca Russo and Umberto Malapelle. Writing—original draft preparation: Francesco Pepe, Gianluca Russo. Writing—review and editing: Giancarlo Troncone and Umberto Malapelle. Visualization: All the authors. Supervision: Giancarlo Troncone and Umberto Malapelle. Project administration: Giancarlo Troncone and Umberto Malapelle. All authors have read and agreed to the published version of the manuscript.

Funding. This study has partly been supported by the following grants: 1. Monitoraggio ambientale, studio ed approfondimento della salute della popolazione residente in aree a rischio—In attuazione della D.G.R. Campanian.180/2019. 2. POR Campania FESR 2014–2020 Progetto “Sviluppo di Approcci Terapeutici Innovativi per patologie Neoplastiche resistenti ai trattamenti—SATIN” 3. The Italian Health Ministry’s research program (ID: NET-2016-02363853). National Center for Gene Therapy and Drugs based on RNA Technology MUR-CN3 CUP E63C22000940007 to DS. No funding or sponsorship was received for the publication of this article.

Data Availability. Data are available on request from the corresponding author. All data relevant to the study are included in the article or uploaded as supplementary information. All data that are publicly available are used in the

writing of this article in the text and the reference list.

Declarations

Conflict of Interest. Pasquale Pisapia has received personal fees as speaker bureau from Novartis for work performed outside of the current study. Giuseppe Perrone has received personal fees (as consultant and/or speaker bureau) from Boehringer Ingelheim, Roche, MSD, Amgen, Diaceutics, Merck, AstraZeneca, Novartis, Daiichi Sankyo, Exact Sciences, Diat-ech Pharmacogenetics unrelated to the current work. Elena Guerini-Rocco has relevant relationship (advisory fees, honoraria, travel accommodation and expenses, grants and non-financial support) with AstraZeneca, Exact Sciences, GlaxoSmithKline (GSK), Novartis, Roche, Thermo Fisher Scientific unrelated to the current work. Nicola Fusco reports honoraria from Merck Sharp and Dohme (MSD), Boehringer Ingelheim, Novartis, AstraZeneca and Daiichi Sankyo unrelated to the current work. Matteo Fassan reports research funding (to the institution) from QED, Macrophage pharma, Astellas, Diaceutics; personal honoraria as invited speaker from Roche, Astellas, AstraZeneca, Incyte, Bristol Myers Squibb (BMS), Merck Serono, Pierre Fabre, GSK, Novartis, Amgen; participation in advisory board for Amgen, Astellas, Roche, Merck Serono, GSK, Novartis, Janssen unrelated to the current work. Umberto Malapelle has received personal fees (as consultant and/or speaker bureau) from Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientific, Eli Lilly, Diaceutics, GSK, Merck and AstraZeneca, Janssen, Diatech, Novartis and Heder a unrelated to the current work. Giancarlo Troncone reports personal fees (as speaker bureau or advisor) from Roche, MSD, Pfizer, Boehringer Ingelheim, Eli Lilly, BMS, GSK, Menarini, AstraZeneca, Amgen and Bayer, unrelated to the current work. Francesco Pepe, Gianluca Russo, Alessandro Venuta, Claudia Scimone, Mariantonia Nacchio, Gaia Goteri, Francesca Barbisan, Caterina Chiappetta, Angelina Pernazza, Domenico Campagna, Marco Giordano, Giovanna Sabarese, Annalisa Altimari, Dario de Biase, Giovanni Tallini,

Daniele Calistri, Elisa Chiadini, Laura Capelli, Alfredo Santinelli, Anna Elisa Gulini, Elisa Pierpaoli, Manuela Badiali, Stefania Murru, Riccardo Murgia, Konstantinos Venetis, Denise Morotti, Andrea Gianatti, Daniela Furlan, Giulio Rossi, Laura Melocchi, Maria Russo, Caterina De Luca, Lucia Palumbo, Saverio Simonelli, Antonella Maffè, Paola Francia di Celle, Tiziana Venesio, Maria Scatolini, Enrico Grosso, Sara Orecchia, Mariangela Balistreri, Elisabetta Zulato, Daniela Reghellin, Elena Lazzari, Maria Santacatterina, Maria Liliana Piredda, Manuela Riccardi, Licia Laurino, Elena Roz, Domenico Longo, Daniela Petronilla Romeo, Carmine Fazzari, Andrea Moreno-Manuel, Giuseppe Diego Puglia, Andrey D. Prijibelski, Daria Shafranskaya, Luisella Righi, Angela Listì, Domenico Vitale, Antonino Iaccarino have nothing to disclose.

Ethical Approval. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Biological material was managed under the authorization of the Department of Public Health at the University of Naples Federico II, Naples. The cell lines used in this study were reference specimens and were not obtained from patients at the institutions. As such, patient informed consent was not applicable for this research. Institutional review board approval for this type of study on artificial samples is not required following the specification reported by The Italian Data Protection Authority.

Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If

material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

1. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. *CA Cancer J Clin.* 2023;73:233–54.
2. Mok TS. Personalized medicine in lung cancer: what we need to know. *Nat Rev Clin Oncol.* 2011;8: 661–8.
3. Rebuzzi SE, Zullo L, Rossi G, et al. Novel emerging molecular targets in non-small cell lung cancer. *Int J Mol Sci.* 2021;22:2625.
4. Sadik H, Pritchard D, Keeling DM, et al. Impact of clinical practice gaps on the implementation of personalized medicine in advanced non-small-cell lung cancer. *JCO Precis Oncol.* 2022. <https://doi.org/10.1200/PO.22.00246>.
5. Šutić M, Vukić A, Baranašić J, et al. Diagnostic, predictive, and prognostic biomarkers in non-small cell lung cancer (NSCLC) management. *J Pers Med.* 2021;11:1102.
6. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *Arch Pathol Lab Med.* 2018;142:321–46.
7. Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. *Crit Rev Oncol Hematol.* 2021;157:103194.
8. Conde E, Rojo F, Gómez J, et al. Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing. *J Clin Pathol.* 2022;75: 145–53.
9. Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. *N Engl J Med.* 2022;387:120–31.

10. De Maglio G, Pasello G, Dono M, et al. The storm of NGS in NSCLC diagnostic-therapeutic pathway: how to sun the real clinical practice. *Crit Rev Oncol Hematol*. 2022;169:103561.
11. Kerr KM, Bibeau F, Thunnissen E, et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. *Lung Cancer*. 2021;154:161–75.
12. Shen CI, Chiang CL, Shiao TH, et al. Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer. *Sci Rep*. 2022;12:13566.
13. Behnke A, Cayre A, De Maglio G, et al. FACILITATE: a real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC. *Pathol Oncol Res*. 2023;29:1610707.
14. Rolfo C, Mack P, Scagliotti GV, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer. *J Thorac Oncol*. 2021;16:1647–62.
15. Vigliar E, Malapelle U, Bellocicini C, de Luca C, Troncone G. Outsourcing cytological samples to a referral laboratory for EGFR testing in non-small cell lung cancer: does theory meet practice? *Cytopathology*. 2015;26:312–7.
16. Roy-Chowdhuri S, Stewart J. Preanalytic variables in cytology: lessons learned from next-generation sequencing—the MD Anderson experience. *Arch Pathol Lab Med*. 2016;140:1191–9.
17. Lozano MD, Zulueta JJ, Echeveste JI, et al. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes. *Oncologist*. 2011;16:877–85.
18. Pisapia P, Pepe F, Baggi A. Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: the KWAY Italian multicenter cost evaluation study. *Crit Rev Oncol Hematol*. 2022;169: 103525.
19. Vigliar E, Iaccharino A, Campione S, et al. PD-L1 expression in cell-blocks of non-small cell lung cancer: the impact of prolonged fixation. *Diagn Cytopathol*. 2020;48:595–603.
20. Malapelle U, Mayo de-Las-Casas C, Rocco D. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. *Br J Cancer*. 2017;116:802–10.
21. De Luca C, Pepe F, Iaccharino A, et al. RNA-based assay for next-generation sequencing of clinically relevant gene fusions in non-small cell lung cancer. *Cancers (Basel)*. 2021;13:139.
22. Pepe F, De Luca C, Smeraglio R, et al. Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples. *J Clin Pathol*. 2019;72:38–45.
23. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. *Genome Med*. 2020;12:8. <https://doi.org/10.1186/s13073-019-0703-1>.
24. Van de Ven M, Koffijberg H, Retèl V, et al. Real-world utilization of biomarker testing for patients with advanced non-small cell lung cancer in a tertiary referral center and referring hospitals. *J Mol Diagn*. 2021;23:484–94.
25. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019;30:863–70.
26. Dolinar A, Grubelnik G, Srebotnik-Kirbiš I, Strojjan Fležar M, Zlajpah M. Optimization of pre-analytical and analytical steps for DNA and RNA analysis of fresh cytology samples. *Cancer Med*. 2022;11:4021–32.
27. Ascierio PA, Bifulco C, Palmieri G, Peters S, Sidiropoulos N. Preanalytic variables and tissue stewardship for reliable next-generation sequencing (NGS) clinical analysis. *J Mol Diagn*. 2019;21:756–67.
28. Dagher G, Becker KF, Bonin S, et al. Pre-analytical processes in medical diagnostics: new regulatory requirements and standards. *N Biotechnol*. 2019;52:121–5.
29. Gristina V, Malapelle U, Galvano A, et al. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: a systematic review and critical appraisal. *Cancer Treat Rev*. 2020;85:101994.
30. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. *N Engl J Med*. 2021;384:2371–81.
31. Jennings LJ, Arcila ME, Corless C, et al. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists. *J Mol Diagn*. 2017;19:341–65.
32. Gibson J, Young S, Leng B, Zreik R, Rao A. Molecular diagnostic testing of cytology specimens:

- current applications and future considerations. *J Am Soc Cytopathol.* 2014;3:280–94.
33. Davies KD, Lomboy A, Lawrence CA, et al. DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer. *J Thorac Oncol.* 2019;14:737–41.
34. Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. *N Engl J Med.* 2020;383:944–57.